Researchers dig into past records to find clues for melanoma immunotherapy success
NCT ID NCT07302607
First seen Jan 06, 2026 · Last updated Jun 18, 2026 · Updated 30 times
Summary
This study reviews medical records of 221 people with advanced melanoma who received immunotherapy between 2013 and 2021. The goal is to find new factors that predict which patients achieve a complete and lasting response. Participants must be 18 or older and have received treatment at Strasbourg University Hospitals. The study does not involve new treatments or direct benefits to participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Service de dermatologie - Réanimation - CHU de Strasbourg - France
RECRUITINGStrasbourg, 67091, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.